At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 9 enrolled
Drug / intervention
Dupilumab 300Mg Solution for Injectiondrug
Likely dose
Dupilumab 300Mg Solution for Injectionfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus: an Open-Label, Single-Arm, Exploratory Study
In Brief
A Phase 2 clinical trial evaluating Dupilumab 300Mg Solution for Injection for Pruritus. Completed, enrolled 9 participants across 1 site.
Detailed Summary
To investigate the potential efficacy of dupilumab in the treatment of moderate to severe chronic hepatic pruritus.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPruritus
CountriesUnited States
CollaboratorsRegeneron Pharmaceuticals
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedFeb 2020
Enrollment StartSep 2020
Primary CompletionSep 2024
TodayJul 2026
First PostedFeb 5, 2020
Enrollment StartSep 1, 2020
Primary CompletionSep 6, 2024
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 6.4 years ago
Interventions
Dupilumab 300Mg Solution for Injectiondrug
Subcutaneous (SC) dupilumab selected for this study is 300 mg every 2 weeks for 18 weeks.